plans at our facility (which are always subject to change at any time) are
to run herceptest concurrently with the aby we use now (clone CB11 from
ventana) until it is established that the two are equivalent (probably 50-75
cases).  i think at that point i think we will drop the herceptest.
it is my understanding from ventana that they aren't expecting FDA approval
on the CB11 clone for at least a year or so.

carrie kyle-byrne
eire@teleport.com